For patients with CTP C cirrhosis, the only PPI advised is esomeprazole at a maximum dosage of 20 mg per day. However, neurological AEs were reported in patients who received a high intravenous dose and in a patient with severe cirrhosis. Only one study provided sub‐analyses for the risk of HE per PPI. If you do not receive an email within 10 minutes, your email address may not be registered, Unable to load your collection due to an error If no European product information was available, the Dutch product information was used. Pantoprazole sodium has active ingredients of pantoprazole sodium. ), and Basel University Hospital, Basel (M.S., A.H., J.S., D.T., T.V.) pharmacokinetics in CTP C patients), our recommendations are limited by the few studies available. Researchers at University of California San Diego School of Medicine have discovered evidence in mice and humans that these medications alter gut bacteria in a way that … Pantoprazole: 52 (83.9) Esomeprazole: 6 (9.7) Omeprazole: 4 (6.5) Dose of PPI b b In patients with esomeprazole or omeprazole the dose equivalent for pantoprazole was calculated and all doses refer to pantoprazole. Guidance was aimed at the oral use of PPIs and categorized by the severity of cirrhosis, using the Child–Turcotte–Pugh (CTP) classification.A total of 69 studies were included. Etude ouverte chez 24 cirrhotiquesComparative kinetic studies with the three proton pump inhibitors omeprazole, lansoprazole and pantoprazole in patients with complete liver cirrhosisPharmacokinetics of lansoprazole after repeated administration in cirrhosis patientsPharmacokinetics: a relevant factor for the choice of a drug?The use of PPI is associated with spontaneous bacterial peritonitis in cirrhotic patients of different ethnic groups: a meta‐analysisProton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta‐analysisProton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta‐analysisSystematic review and meta‐analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitisAssociation between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta‐analysisUse of proton pump inhibitors in the management of gastroesophageal varices: a systematic reviewLetter: proton pump inhibitors and prognosis of cirrhosis – searching for the balance pointProton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascitesImpact of long‐term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosisProton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective studyLong‐term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosisHealthcare‐associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcomeThe chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosisProton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association?Bacterial infection in compensated viral cirrhosis impairs 5‐year survival (ANRS CO12 CirVir prospective cohort)Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort studyProton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascitesProton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosisBacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeabilityRisk of spontaneous bacterial peritonitis associated with gastric acid suppressionMortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitisAssociation between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascitesProton pump inhibitor use is associated with spontaneous bacterial peritonitis in patients with liver cirrhosisRole of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascitesDose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizationsIncreased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppressionRole of proton pump inhibitors in the development of spontaneous bacterial peritonitis amongst cirrhotics; a retrospective cohort studyAssociation between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascitesClostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspectiveAssociation of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascitesProton pump inhibitor (PPI) use is independently associated with spontaneous bacterial peritonitis (SBP) in cirrhotics with ascitesAssociation between proton pump inhibitor use and spontaneous bacterial peritonitisChronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patientsStereoselective disposition of proton pump inhibitorsSystematic review: the influence of CYP2C19 polymorphism on the acid‐inhibitory effects of proton pump inhibitorsEsomeprazole‐induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic dataEndoscopic and Pharmacologic Management of Upper GI Bleeding, Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?, Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies, Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients, Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis, Comparative Pharmacokinetic Study of Taxifolin after Oral Administration of Fructus Polygoni Orientalis Extract in Normal and Fibrotic Rats by UPLC-MS/MS, Evidence-Based Complementary and Alternative Medicine, Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis, Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis, Endoscopic and Pharmacologic Management of Upper GI Bleeding, Leberzirrhose und Komplikationen rechtzeitig erkennenHepatic cirrhosis: early diagnosis and prevention of complications, Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis, Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations, Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study,